Gillian Murphy
#134,946
Most Influential Person Now
Gillian Murphy's AcademicInfluence.com Rankings
Gillian Murphybiology Degrees
Biology
#9172
World Rank
#12342
Historical Rank
Molecular Biology
#1228
World Rank
#1254
Historical Rank
Biochemistry
#1376
World Rank
#1500
Historical Rank

Download Badge
Biology
Gillian Murphy's Degrees
- PhD Biochemistry University of California, Berkeley
- Bachelors Chemistry Stanford University
Why Is Gillian Murphy Influential?
(Suggest an Edit or Addition)Gillian Murphy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Structure and function of matrix metalloproteinases and TIMPs. (2006) (2935)
- Metalloproteinase inhibitors: biological actions and therapeutic opportunities (2002) (1116)
- Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity (1985) (700)
- A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 (2003) (657)
- Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). (2001) (639)
- The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A (1998) (627)
- TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 (1998) (583)
- Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. (1997) (473)
- Mechanisms for pro matrix metalloproteinase activation (1999) (450)
- Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. (1987) (449)
- Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). (1991) (447)
- The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 (2000) (421)
- Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase (2000) (418)
- Degradation of cartilage aggrecan by collagenase‐3 (MMP‐13) (1996) (393)
- Tissue inhibitor of metalloproteinase‐1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis (1996) (337)
- The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. (1991) (328)
- ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. (2000) (327)
- Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? (1997) (315)
- Correction for Substrate Selectivity of Epidermal Growth Factor-Receptor Ligand Sheddases and their Regulation by Phorbol Esters and Calcium Influx (2006) (305)
- TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. (1998) (297)
- Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 (1999) (296)
- The role of the C-terminal domain in collagenase and stromelysin specificity. (1992) (290)
- Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? (2008) (287)
- The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. (1992) (280)
- The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. (1992) (271)
- Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). (2002) (257)
- ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking (2005) (254)
- Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. (1999) (251)
- Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface (2003) (250)
- Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes (*) (1995) (247)
- The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a (1992) (245)
- Identification and structural and functional characterization of human enamelysin (MMP-20). (1997) (238)
- The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. (1993) (236)
- ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. (2002) (235)
- Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* (2000) (224)
- Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. (1994) (221)
- Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. (1992) (214)
- Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. (1991) (206)
- Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. (1989) (197)
- Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). (1997) (195)
- Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. (1999) (195)
- Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. (2000) (188)
- Accelerated apoptosis in the Timp-3-deficient mammary gland. (2001) (187)
- The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. (1990) (186)
- Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1 (2012) (184)
- The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. (1992) (183)
- Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. (1997) (180)
- Matrix Metalloproteinases MMP2 and MMP9 Are Produced in Early Stages of Kidney Morphogenesis but Only MMP9 Is Required for Renal Organogenesis In Vitro (1997) (176)
- Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* (2006) (171)
- High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. (2000) (167)
- Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. (1991) (160)
- Src-mediated Tyrosine Phosphorylation of Caveolin-1 Induces Its Association with Membrane Type 1 Matrix Metalloproteinase* (2004) (160)
- Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. (1989) (156)
- Evidence for a Critical Role of the Tumor Necrosis Factor α Convertase (TACE) in Ectodomain Shedding of the p75 Neurotrophin Receptor (p75NTR)* (2004) (155)
- Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. (1994) (155)
- Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer (1999) (155)
- Physiological mechanisms for metalloproteinase activation. (1992) (152)
- Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. (2010) (152)
- The matrix metalloproteinases and their inhibitors. (1995) (151)
- Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. (1993) (151)
- The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs (2002) (147)
- The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. (1993) (146)
- Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. (2002) (144)
- Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases* (2004) (141)
- Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. (1997) (141)
- The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. (1996) (139)
- Matrix metalloproteinases and metastatic cancer. (1998) (131)
- Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. (1993) (131)
- Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. (1994) (129)
- Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. (2001) (129)
- Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation* (2006) (125)
- Extracellular regulation of metalloproteinases. (2015) (124)
- A Heterogeneous In Vitro Three Dimensional Model of Tumour-Stroma Interactions Regulating Sprouting Angiogenesis (2012) (122)
- Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes (2011) (121)
- Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. (2005) (119)
- Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. (1995) (119)
- Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. (1994) (118)
- Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. (1993) (118)
- Cross-domain inhibition of TACE ectodomain (2011) (116)
- The matrix metalloprotease matrilysin (PUMP) is expressed in developing human mononuclear phagocytes. (1992) (114)
- Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. (2005) (112)
- Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. (2005) (112)
- Cellular activation of proMMP‐13 by MT1‐MMP depends on the C‐terminal domain of MMP‐13 (2002) (109)
- Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. (1994) (106)
- Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. (2001) (105)
- Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles* (2015) (103)
- Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. (2000) (102)
- Structure-function relationships in the tissue inhibitors of metalloproteinases. (1994) (101)
- The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. (2008) (100)
- Human and rat malignant-tumor-associated mRNAs encode stromelysin-like metalloproteinases. (1989) (98)
- ADAM28 is overexpressed in human non‐small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis (2006) (98)
- Catalytic activities of membrane‐type 6 matrix metalloproteinase (MMP25) (2001) (95)
- Human myeloma cells shed the interleukin‐6 receptor: inhibition by tissue inhibitor of metalloproteinase‐3 and a hydroxamate‐based metalloproteinase inhibitor (1998) (95)
- Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. (1994) (94)
- Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. (1990) (92)
- Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor Transactivation (2007) (91)
- Effects of collagenase-cleavage of type I collagen on alpha2beta1 integrin-mediated cell adhesion. (1998) (91)
- Metalloproteinases and tissue damage. (1991) (88)
- Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. (2001) (86)
- The Specificity of TIMP-2 for Matrix Metalloproteinases Can Be Modified by Single Amino Acid Mutations* (1999) (86)
- Role and regulation of metalloproteinases in connective tissue turnover. (1990) (86)
- Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. (1999) (85)
- Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. (1992) (84)
- CD30 Shedding from Karpas 299 Lymphoma Cells Is Mediated by TNF-α-Converting Enzyme1 (2000) (84)
- Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. (1992) (83)
- Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * (2003) (82)
- Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma (2006) (82)
- Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. (1993) (82)
- Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor (2002) (82)
- Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. (1994) (80)
- Membrane-type 1-Matrix Metalloproteinase Regulates Intracellular Adhesion Molecule-1 (ICAM-1)-mediated Monocyte Transmigration* (2007) (78)
- Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo (2012) (77)
- Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis. (2002) (76)
- Activation of human neutrophil procollagenase by stromelysin 2. (1996) (75)
- Membrane-Type Matrix Metalloproteinases and Cell Surface-Associated Activation Cascades for Matrix Metalloproteinases (1998) (71)
- Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. (2006) (70)
- Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1* (2007) (70)
- Immunolocalization of Matrix Metalloproteinases in Partial-Thickness Defects in Pig Articular Cartilage: A Preliminary Report (2001) (69)
- MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src (2010) (68)
- Unveiling the Surface Epitopes That Render Tissue Inhibitor of Metalloproteinase-1 Inactive against Membrane Type 1-Matrix Metalloproteinase* (2003) (67)
- ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer (2014) (67)
- Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. (1991) (66)
- Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical (2005) (66)
- TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4* (2007) (65)
- New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). (2004) (65)
- Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. (1989) (65)
- Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. (2006) (65)
- Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1. (1994) (64)
- Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. (2003) (60)
- Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. (2001) (59)
- The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. (2010) (59)
- Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. (2001) (59)
- Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. (1996) (58)
- Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). (2003) (57)
- Total Conversion of Tissue Inhibitor of Metalloproteinase (TIMP) for Specific Metalloproteinase Targeting (2005) (57)
- Proteolytic inactivation of human α1 antitrypsin by human stromelysin (1991) (56)
- Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity (2016) (56)
- Threonine 98, the Pivotal Residue of Tissue Inhibitor of Metalloproteinases (TIMP)-1 in Metalloproteinase Recognition* (2004) (54)
- Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate. (1998) (54)
- CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. (2000) (54)
- The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. (1996) (53)
- Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells. (2000) (52)
- Proteolysis of human native and oxidised α1-proteinase inhibitor by matrulysin and stromelysin (1994) (51)
- Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells (2015) (51)
- Stromelysin (MMP‐3) Synthesis Is Up‐Regulated in Estrogen‐Deficient Mouse Osteoblasts In Vivo and In Vitro (1999) (51)
- Interaction of metargidin (ADAM-15) with αvβ3 and α5β1 integrins on different haemopoietic cells (1999) (50)
- Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. (1996) (50)
- Expression of the type IV collagenase system during mouse kidney development and tubule segmentation. (2001) (49)
- Senescence‐associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding (2014) (48)
- Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. (2002) (45)
- The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. (2008) (43)
- Inhibition of Shedding of Low‐Density Lipoprotein Receptor–Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis (2017) (43)
- Chemically and conformationally authentic active domain of human tissue inhibitor of metalloproteinases-2 refolded from bacterial inclusion bodies. (1996) (42)
- Expression and modulation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in human embryonic CNS stem cells. (1999) (42)
- Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation (2014) (41)
- Metalloproteinase domain structure, cellular invasion and metastasis. (1994) (41)
- Altered MicroRNA Expression after Infection with Human Cytomegalovirus Leads to TIMP3 Downregulation and Increased Shedding of Metalloprotease Substrates, Including MICA (2014) (41)
- Meltrin γ (ADAM-9) mediates cellular adhesion through α6β1 integrin, leading to a marked induction of fibroblast cell motility (2000) (40)
- Gelatinase A possesses a β‐secretase‐like activity in cleaving the amyloid protein precursor of Alzheimer's disease (1995) (40)
- Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. (1992) (38)
- Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. (2012) (38)
- Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. (2005) (38)
- Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). (2010) (38)
- Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. (2000) (38)
- Role of the Netrin-like Domain of Procollagen C-Proteinase Enhancer-1 in the Control of Metalloproteinase Activity* (2010) (38)
- Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro‐angiogenic phenotype and increased cell motility and invasiveness (2011) (37)
- Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2) (2015) (37)
- MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3 (2008) (36)
- Two novel determinants of etoposide resistance in small cell lung cancer. (2011) (36)
- Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)‐3 using TIMP‐1 as the scaffold: A new frontier in TIMP engineering (2002) (35)
- Golgi reassembly stacking protein 55 interacts with membrane‐type (MT) 1‐matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1‐MMP zymogen (2010) (34)
- Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo (2016) (34)
- Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer (2010) (33)
- The C‐terminal domains of TACE weaken the inhibitory action of N‐TIMP‐3 (2002) (33)
- Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. (2002) (32)
- Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption (2017) (32)
- N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. (2005) (32)
- Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis* (2015) (32)
- Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex (2012) (31)
- LPS activates ADAM9 dependent shedding of ACE from endothelial cells. (2012) (31)
- Delineating the Molecular Basis of the Inactivity of Tissue Inhibitor of Metalloproteinase-2 against Tumor Necrosis Factor-α-converting Enzyme* (2004) (31)
- Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice (2013) (30)
- Tailoring TIMPs for Selective Metalloproteinase Inhibition (2008) (30)
- Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. (2014) (30)
- Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Ubiquitination at Lys581 Increases Cellular Invasion through Type I Collagen* (2012) (30)
- Lactoferricin mediates anabolic and anti‐catabolic effects in the intervertebral disc (2012) (30)
- Establishment and Characterization of 7 New Monoclonal Antibodies to Tissue Inhibitor of Metalloproteinases-1 (2005) (28)
- Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (28)
- BA321, a novel carborane analog that binds to androgen and estrogen receptors, acts as a new selective androgen receptor modulator of bone in male mice. (2016) (27)
- The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. (2010) (27)
- Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration (2011) (26)
- Adam 33 and its association with airway remodeling and hyperresponsiveness in asthma (2004) (26)
- The Recognition Sites of the Integrins α1β1 and α2β1 within Collagen IV Are Protected against Gelatinase A Attack in the Native Protein* (1996) (26)
- Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. (2003) (26)
- Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK‐1 in HT1080 fibrosarcoma cells (2004) (25)
- Tissue Banking of Diagnostic Lung Cancer Biopsies for Extraction of High Quality RNA (2010) (25)
- Granulocyte‐macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane‐type 1 matrix metalloproteinase expression in vitro (2008) (24)
- Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. (2005) (23)
- Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. (2004) (23)
- The regulation of connective tissue metalloproteinases by natural inhibitors. (1991) (22)
- A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. (2005) (22)
- ADAM 33: just another asthma gene or a breakthrough in understanding the origins of bronchial hyperresponsiveness? (2003) (22)
- The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer* (2016) (21)
- Anti‐tumor effects of a ‘human & mouse cross‐reactive’ anti‐ADAM17 antibody in a pancreatic cancer model in vivo (2017) (20)
- Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (19)
- Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. (1994) (18)
- Effects of collagenase-cleavage of type I collagen on α 2 β 1 integrin-mediated cell adhesion (1998) (17)
- Folding and stability of the active N-terminal domain of tissue inhibitor of metalloproteinases-1 and -2. (1994) (17)
- The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity. (2001) (16)
- TIMP-3 facilitates binding of target metalloproteinases to the endocytic receptor LRP-1 and promotes scavenging of MMP-1 (2019) (16)
- Characterization of the AB Loop Region of TIMP-2 (2006) (14)
- Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. (1995) (13)
- MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. (2006) (13)
- Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping. (1993) (13)
- Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor (2002) (13)
- The Aminopeptidase CD13 Induces Homotypic Aggregation in Neutrophils and Impairs Collagen Invasion (2016) (12)
- ADAM9 is present at endothelial cell - cell junctions and regulates monocyte – endothelial transmigration (2017) (12)
- ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (12)
- Proteolytic inactivation of human alpha 1 antitrypsin by human stromelysin. (1991) (11)
- Mechanism of Heparin Acceleration of Tissue Inhibitor of Metalloproteases-1 (TIMP-1) Degradation by the Human Neutrophil Elastase (2011) (10)
- One-step Sandwich Enzyme Immunoassays for Human Matrix Metalloproteinase 13(Collagenase-3)using Monoclonal Antibodies (1998) (10)
- Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. (1989) (10)
- Tissue Inhibitor of Metalloproteinase–3 (TIMP-3) induces FAS dependent apoptosis in human vascular smooth muscle cells (2018) (10)
- The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein. (1996) (9)
- Two Secreted Proteoglycans, Activators of Urothelial Cell–Cell Adhesion, Negatively Contribute to Bladder Cancer Initiation and Progression (2020) (8)
- Isolation and characterisation of a chicken gelatinase (type IV collagenase). (1991) (8)
- Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis. (2018) (7)
- Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1 (2017) (7)
- Assessment of gelatinase expression and activity in articular cartilage. (2007) (7)
- Crystallization and preliminary X-ray analysis of a truncated tissue metalloproteinase inhibitor delta 128-194 TIMP-2. (1993) (7)
- Erratum: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family (Journal of Biological Chemistry (1995) 270 (14313-14318)) (1996) (7)
- Methods for studying activation of matrix metalloproteinases. (2010) (6)
- Identification and possible functions of ADAM33 as an asthma susceptibility gene (2004) (6)
- Methods for studying activation of matrix metalloproteinases. (2001) (6)
- COLLAGENASE-3 (MMP-13) C-TERMINAL HEMOPEXIN-LIKE DOMAIN (1996) (5)
- Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases. (2016) (5)
- N-terminal domain of tissue inhibitor of metalloproteinase ( TIMP )-3 to be a better inhibitor against tumour necrosis factor-α-converting enzyme (4)
- Speci ¢ c collagenolysis by gelatinase A , MMP-2 , is determined by the hemopexin domain and not the ¢ bronectin-like domain (2001) (4)
- Evidence for the importance of weakly bound water for matrix metalloproteinase activity. (1995) (4)
- 1 Role of the NTR domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity * (2010) (4)
- Metalloproteinases in Cartilage Matrix Breakdown: The Roles in Rheumatoid Arthritis and Osteoarthritis (2013) (4)
- ADAM 17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (4)
- Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. (2002) (4)
- Molecular biology (pre-clinical) (2012) (3)
- The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitor activity [Erratum to document cited in CA115(9):88133x] (1991) (3)
- Advances in Brief Identification and Characterization of Human MT 5-MMP , a New Membrane-bound Activator of Progelatinase A Overexpressed in Brain Tumors 1 (2000) (3)
- MT 1-MMP hemopexin domain exchange with MT 4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF 7 cells (2006) (2)
- Biochemistry meets biology: key findings for bone calcification and a lifetime philosophy of collaboration (2011) (2)
- Inhibition of LRP1 shedding reverses cartilage degradation in osteoarthritis (2018) (2)
- Role of collagenase-3 (MMP-13) in cartilage resportion as observed during the development of the secondary ossification center in the tibia of young rates. I. synthesis and secretion of procollagenase-3 at sites of cartilage (2003) (1)
- Membrane type matrix metalloproteinases: regulators of focal proteolysis (1999) (1)
- Tissue Inhibitor of Metalloproteinase-1 is Expressed by Hepatic Lipocytes and Upregulated in Cirrhosis and CCl4-Induced Liver (1994) (1)
- ArticleTwo Secreted Proteoglycans (2020) (0)
- Involvement of collagenase-3 (MMP-13) in the collagen breakdown required for the excavation of the cartilaginous epiphysis of the developing rat long bone (2002) (0)
- Carbachol induces ERK1/2 activation and stimulates cell proliferation via a metalloproteinase- and Tgfα-dependent pathway (2003) (0)
- 527 ADAM17 as a Therapeutic Target for the Treatment of Breast Cancer: Preclinical Studies with an Inhibitory Monoclonal Antibody (2012) (0)
- Study of the distribution of metalloproteinases and their tissue inhibitor in human mammary gland lesions. (1990) (0)
- 129 – Gelatinase A (2004) (0)
- The role of matrix metalloproteinases (MMPs) in the arthritides (1998) (0)
- The trap hypothesis: α2M and protease inhibition (2006) (0)
- MMP-2, MMP-9 and MMP-14 in Breast cancer : clinicalpathological correlation. (2010) (0)
- Modulation of Matrix Metalloproteinases Controls Fibroblast Scarring Activity and Minimises Ocular Scarring following Experimental Surgery (2003) (0)
- Abstract 328: ADAM17-induced activation of HER receptors mediate resistance to trastuzumab in a subset of moderate HER2-expressing breast cancer cells (2019) (0)
- Down-regulation of MT1-MMP leads to inhibition of invasion and increased expression of anti-migratory gene in urothelial carcinoma cell line (2007) (0)
- Calcium pentosan polysulfate increases affinity between aggrecanases (ADAMTS-4 and-5) and TIMP-3 by a conformational change (2010) (0)
- Enzyme -Converting a Cells Is Mediated by TNF-CD30 Shedding from Karpas 299 Lymphoma (2000) (0)
- The trap hypothesis: alpha2M and protease inhibition (2006) (0)
- S93 Is Bcl-2 important in small cell lung cancer? (2010) (0)
- 86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer (2012) (0)
- Design, Synthesis and Inhibitory Properties of Potent Sulfonyl Diaryl Based MMPs and TACE inhibitors (2005) (0)
- MMPs and ADAMs as targets for therapies in arthritis (2007) (0)
- 432 ADAM17 is a psoriasis-relevant check-point controlling Th17-programming by inflammatory dermal dendritic cells (2016) (0)
- Crystal structure of MMP-1(E200A) in complex with a triple-helical collagen peptide (2012) (0)
- Chapter 37 Tailoring TIMPs for Selective Metalloproteinase Inhibition (0)
- Design, synthesis and biological properties of new potent and selective sulfonamide-based inhibitors of gelatinase A (2003) (0)
- Mechanism of Induction of Choroidal Neovascularization in Sorsby Fundus Dystrophy (2003) (0)
- INTERLEUKIN-1 ALPHA STIMULATES ADAM17-MEDIATED ECTODOMAIN SHEDDING OF LRP1 AND REDUCES ENDOCYTOSIS OF AGGRECANASES IN ARTICULAR CARTILAGE (2015) (0)
- Abstract 2724: Activity of the specific anti-ADAM17 inhibitory IgG antibody (Ab), D1(A12) in an ovarian cancer modelin vivo (2012) (0)
- MMP inhibition modulates protease production and matrix contraction by myofibroblasts in mechanically loaded collagen gels. (2004) (0)
- Extracellular regulation of Kazuhiro Yama (2015) (0)
- Matrix Metallopeptidase-2/Gelatinase A (2013) (0)
- Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins (2007) (0)
- Matrix metalloproteinase expression and function in urothelial carcinoma (2005) (0)
- Molecular mechanisms of acetylcholine-induced ERK1/2 activation in HT29 cells and isolated human colonic crypts (2002) (0)
- Syddansk Universitet Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo Botkjaer, (2016) (0)
- Design of Selective Collagenase 3 (MMP-13) Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis (2008) (0)
- ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells (2019) (0)
- Carbachol induced calcium signals induce metalloproteinase dependent shedding of TGFα and downstream activation of mitogenic epidermal growth factor receptor signals in HT29 colonic epithelial cells (2004) (0)
- ADAM17, Tumor Necrosis Factor α-Convertase (2013) (0)
- Inhibition of LRP1 shedding reverses cartilage matrix degradation in osteoarthritis (2017) (0)
- Abstract 557: Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gillian Murphy?
Gillian Murphy is affiliated with the following schools: